World Health Organization Raises Concern Over Acute Shortage of Obesity Jabs

Less than one in 10 people that would benefit from obesity jabs like Wegovy are able to get them, warns the WHO as it issues its first guidance on the drugs.

Considering more than one billion people worldwide currently obese, it is advocating for increased and just availability to these injectable treatments.

According to forecasts, more than two billion could be obese by 2030 unless action is taken.

"Our latest guidance acknowledges that obesity is a long-term condition that can be treated with thorough and continuous support," said WHO director-general Tedros Adhanom Ghebreyesus.

Significant expense, limited production capacity, and logistical bottlenecks are significant hurdles to broad availability to the injections that can assist patients in reducing significant body mass, notes the agency.

Skinny Jab Shortage

Even in the current most favorable case, the production of these medications would only suffice for approximately 100 million people – less than 10% of the global need, as stated by the health organization.

The recommendation calls on governments and firms to increase access, by measures including voluntary licensing.

A patent on semaglutide – the primary ingredient of a leading brand – is scheduled to end in a number of nations in 2026.

How Weight-Loss Jabs Operate

GLP-1 drugs imitate a biological compound to slow digestion, curb appetite and increase satiety so individuals eat less.

People commonly begin shedding pounds in the initial weeks of beginning the weekly injections.

Evidence points to users may put most of the weight back on a year later of stopping the medication, when their usual hunger come back.

Being overweight or obese raises your chance for developing health problems, like diabetes, cardiovascular issues, stroke, and some cancers.

Excess weight concerns individuals in countries worldwide and was responsible for millions of fatalities worldwide in 2024, as per the WHO.